论文信息 - Brand inequity in access to COVID-19 vaccines - 字舞流文

Brand inequity in access to COVID-19 vaccines

M. Sheel | S. Davies | S. McEwen

[1] M. Pai,et al. Vax the world , 2021, Science.

[2] Laurin B. Weissinger,et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries , 2021, Nature Medicine.

[3] C. Macintyre,et al. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia , 2021, Vaccine.

[4] N. Jecker,et al. What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines , 2021, Journal of Medical Ethics.

[5] A. Usher. A beautiful idea: how COVAX has fallen short , 2021, The Lancet.

[6] M. Jit,et al. Divergent vaccination policies could fuel mistrust and hesitancy , 2021, The Lancet.

[7] D. Isaacs. The precautionary principle, the AstraZeneca COVID‐19 vaccine and mixed messaging , 2021, Journal of paediatrics and child health.

[8] M. Jit,et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment , 2021, The Lancet.